Triggering Factors in Drug Delivery Devices

Author(s): Anton Ficai.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 2 , 2019


[1]
Yang SD, Wang Y, Ren ZX, Chen MT, Chen WL, Zhang XN. Stepwise pH/reduction-responsive polymeric conjugates for enhanced drug delivery to tumor. Mat Sci Eng C-Mater 2018; 82: 234-43.
[2]
Wu JL, Zhang HY, Hu X, et al. Reduction-sensitive mixed micelles assembled from amphiphilic prodrugs for self-codelivery of DOX and DTX with synergistic cancer therapy. Colloid Surface B 2018; 161: 449-56.
[3]
Sun HL, Zhang YF, Zhong ZY. Reduction-sensitive polymeric nanomedicines: An emerging multifunctional platform for targeted cancer therapy. Adv Drug Deliver Rev 2018; 132: 16-32.
[4]
Yu M, Guo F, Tan FP, Li N. Dual-targeting nanocarrier system based on thermosensitive liposomes and gold nanorods for cancer thermo-chemotherapy. J Control Release 2015; 215: 91-100.
[5]
Taghizadeh B, Taranejoo S, Monemian SA, et al. Classification of stimuli-responsive polymers as anticancer drug delivery systems. Drug Deliv 2015; 22(2): 145-55.
[6]
Qiao YT, Wan JQ, Zhou LQ, et al. Stimuli-responsive nanotherapeutics for precision drug delivery and cancer therapy. Wires Nanomed Nanobi 2019; 11(1)
[7]
Zuo MZ, Qian WR, Xu ZQ, et al. Multiresponsive supramolecular theranostic nanoplatform based on pillar[5]arene and diphenylboronic acid derivatives for integrated glucose sensing and insulin delivery. Small 2018; 14(38)
[8]
Zhou L, Wang H, Li YP. Stimuli-responsive nanomedicines for overcoming cancer multidrug resistance. Theranostics 2018; 8(4): 1059-74.
[9]
Zhao TC, Chen L, Li Q, Li XM. Near-infrared light triggered drug release from mesoporous silica nanoparticles. J Mater Chem B 2018; 6(44): 7112-21.
[10]
Andronescu E, Ficai M, Voicu G, Ficai D, Maganu M, Ficai A. Synthesis and characterization of collagen/hydroxyapatite: magnetite composite material for bone cancer treatment. J Mater Sci Mater M 2010; 21(7): 2237-42.
[11]
Sonmez M, Ficai D, Ficai A, et al. Applications of mesoporous silica in biosensing and controlled release of insulin. Int J Pharmaceut 2018; 549(1-2): 179-200.
[12]
Arruda FdS., Tome FD, Miguel MP, et al. Doxorubicin-induced cardiotoxicity and cardioprotective agents: classic and new players in the game. Curr Pharm Des 2019; 25(2): 109-18.
[13]
Ficai D, Ficai A, Andronescu E. Perspectives in cancer diagnosis and treatment. Anti-Cancer Agent Me 2019.
[14]
Shah N, Dizon DS. New-generation platinum agents for solid tumors. Future Oncol 2009; 5(1): 33-42.
[15]
Croitoru A, Ficai D, Craciun L, Ficai A, Andronescu E. Evaluation and exploitation of bioactive compounds of walnut, Juglans regia. Curr Pharm Des 2019; 25(2): 119-31.
[16]
Surman M, Drożdż A, Stępień E, Przybyło M. Extracellular vesicles as drug delivery systems - methods of production and potential therapeutic applications. Curr Pharm Des 2019; 25(2): 132-54.
[17]
Xu XL, Lu KJ, Yao XQ, Ying XY, Du YZ. Stimuli-responsive drug delivery systems as an emerging platform for treatment of rheumatoid arthritis. Curr Pharm Des 2019; 25(2): 155-65.
[18]
Zaric BL, Obradovic M, Sudar-Milovanovic E, Nedeljkovic J, Lazic V, Isenovic ER. Drug delivery systems for diabetes treatment. Curr Pharm Des 2019; 25(2): 166-73.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 2
Year: 2019
Page: [107 - 108]
Pages: 2
DOI: 10.2174/138161282502190514121641

Article Metrics

PDF: 13
HTML: 5
EPUB: 1
PRC: 1

Special-new-year-discount